Press Releases Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-06 EDT			5-day change	1st Jan Change
402.5 ^USD	+0.35%		+1.59%	-1.08%

05-06	Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase	MT
05-06	Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vertex: Q1 Earnings Snapshot	05-06	AQ
Vertex Reports First Quarter 2024 Financial Results	05-06	BU
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older	04-26	BU
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	04-23	PR
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	04-23	AQ
Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain	04-19	AQ
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain	04-18	BU
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers	04-15	AQ
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences	04-10	BU
Vertex to Announce First Quarter 2024 Financial Results on May 6	04-09	BU
Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	04-02	AQ
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	04-01	AQ
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	04-01	BU
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	03-28	AQ
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"	03-25	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	03-22	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	03-21	BU
Vertex Pharmaceuticals Incorporated : ID&E Fact Sheet	03-04	PU
Vertex Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older	02-26	AQ
Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older	02-23	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Press Releases

Filters